Next Article in Journal
Self-Generated Lower Body Negative Pressure Exercise: A Low Power Countermeasure for Acute Space Missions
Previous Article in Journal
Anti-SARS-CoV-2 Neutralizing Responses in Various Populations: Use of a Rapid Surrogate Lateral Flow Assay and Correlations with Anti-RBD Antibody Levels
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Life
Volume 14
Issue 7
10.3390/life14070792
life-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Systematic Review

Exploring Study Design Foibles in Randomized Controlled Trials on Convalescent Plasma in Hospitalized COVID-19 Patients

by
Massimo Franchini
1,*,
Carlo Mengoli
1,
Arturo Casadevall
2 and
Daniele Focosi
3,*
1
Department of Hematology and Transfusion Medicine, Carlo Poma Hospital, 46100 Mantua, Italy
2
Johns Hopkins Bloomberg School of Public Health, Department of Molecular Microbiology and Immunology, Baltimore, MD 21205, USA
3
North-Western Tuscany Blood Bank, Pisa University Hospital, 56124 Pisa, Italy
*
Authors to whom correspondence should be addressed.
Life 2024, 14(7), 792; https://0-doi-org.brum.beds.ac.uk/10.3390/life14070792
Submission received: 29 April 2024 / Revised: 19 June 2024 / Accepted: 20 June 2024 / Published: 22 June 2024
(This article belongs to the Topic Multifaceted Efforts from Basic Research to Clinical Practice in Controlling COVID-19 Disease)
Browse Figure
Versions Notes

Abstract

:
Background: Sample size estimation is an essential step in the design of randomized controlled trials (RCTs) evaluating a treatment effect. Sample size is a critical variable in determining statistical significance and, thus, it significantly influences RCTs’ success or failure. During the COVID-19 pandemic, many RCTs tested the efficacy of COVID-19 convalescent plasma (CCP) in hospitalized patients but reported different efficacies, which could be attributed to, in addition to timing and dose, inadequate sample size estimates. Methods: To assess the sample size estimation in RCTs evaluating the effect of treatment with CCP in hospitalized COVID-19 patients, we searched the medical literature between January 2020 and March 2024 through PubMed and other electronic databases, extracting information on expected size effect, statistical power, significance level, and measured efficacy. Results: A total of 32 RCTs were identified. While power and significance level were highly consistent, heterogeneity in the expected size effect was relevant. Approximately one third of the RCTs did not reach the planned sample size for various reasons, with the most important one being slow patient recruitment during the pandemic’s peaks. RCTs with a primary outcome in favor of CCP treatment had a significant lower median absolute difference in the expected size effect than unfavorable RCTs (20.0% versus 33.9%, P = 0.04). Conclusions: The analyses of sample sizes in RCTs of CCP treatment in hospitalized COVID-19 patients reveal that many underestimated the number of participants needed because of excessively high expectations on efficacy, and thus, these studies had low statistical power. This, in combination with a lower-than-planned recruitment of cases and controls, could have further negatively influenced the primary outcomes of the RCTs.

1. Introduction

Similar to what happened in several previous infectious outbreaks, plasma collected from recovered subjects was the first antibody-based therapy used to fight the recent COVID-19 pandemic [1,2]. In the USA, COVID-19 convalescent plasma (CCP) was first deployed under a registry [3]. After an analysis of registry data had identified a signal of efficacy [4], the Food and Drug Administration (FDA) issued emergency use authorization, which led to CCP transfusions in more than 500,000 COVID-19 patients [5]. In addition, CCP was the most intensively studied anti-SARS-CoV-2 therapeutic agent in the COVID-19 pandemic, with nearly 50 randomized controlled trials (RCTs) focusing on CCP being published (Supplementary Table S1) [6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52]. Such trials have identified the correct place for CCP among therapies against COVID-19, and it is more effective in blocking viral replication and disease progression when transfused with a high concentration of anti-SARS-CoV-2 neutralizing antibodies (nAbs) at the early stage (i.e., within 5 days from symptom onset), particularly in seronegative immunocompromised patients [53,54,55]. While previous RCTs have consistently showed that early CCP administration in COVID-19 outpatients is effective in reducing disease progression and the risk of hospitalization, later studies on the in-hospital use of CCP have yielded mixed results [56,57]. Various underlying factors have been suggested to be contribute to the discrepancy of results, including differences in nAb titers, inpatient characteristics, and the timing of CCP transfusion [58]. Furthermore, differences in study design among RCTs conducted during the four-year pandemic period may have been another reason. In particular, heterogeneity in sample size estimation, which is a parameter of power analysis closely related to the treatment effect and is crucial for determining the success or failure of a trial, is likely to have played a critical role in suboptimal study designs [59,60].
In this study, we systematically investigated the sample size calculations of published RCTs evaluating CCP treatment in hospitalized COVID-19 patients.

2. Material and Methods

The aim of this systematic review was to evaluate sample size calculation and its possible influence on study results in RCTs conducted on using CCP treatment in patients hospitalized for COVID-19. A literature search of the PubMed (through Medline), EMBASE, Cochrane central, medRxiv, and bioRxiv databases was carried out between 1 January 2020 and 31 March 2024, using the English language as a filter. The Medical Subject Heading (MeSH) and search queries used were as follows: “(“COVID-19” OR “SARS-CoV-2” OR “coronavirus disease 2019”) AND (“convalescent plasma” OR “immune plasma” or “hyperimmune plasma”) AND (“randomized trial” OR “RCT”)”. We also screened the reference list of all the retrieved studies and review articles for additional studies not captured in our initial literature search. Finally, a PRISMA flowchart of the literature reviewing process was produced, and it is shown in Figure 1.
Only RCTs that enrolled patients hospitalized with COVID-19 of any disease severity and treated with CCP were included in this systematic review. The exclusion criteria were outpatient setting and the absence of a sample size calculation (sample size estimation was retrieved from the ‘Method’ section of each published study and/or from the study design of the registered protocol). The CCP treatment (intervention) was compared with any controls (i.e., standard treatment, placebo, CCP, or standard plasma). The following parameters were extracted from each study (Table 1 and Supplementary Table S1): study design, date of initial recruitment of patients, sample size estimation (expected size effect, statistical power, and significance level), number of expected and number of actually enrolled cases and controls, early termination of the study (and cause of study termination), primary outcome, and 28-day mortality rate (when present, reported as primary or secondary) in the CCP and control arms. When possible, the expected size effect was calculated as absolute or relative difference to render the results from different studies homogeneous and comparable. The articles underwent an independent evaluation for inclusion by two assessors (M.F. and D.F.), and disagreements were resolved by a third senior assessor (C.M.).
Within-trial Risk of Bias (ROB) was assessed using the Cochrane ROB tool for RCTs. The Cochrane ROB tool for RCTs addresses six specific domains: sequence generation, allocation concealment, blinding, incomplete data, selective outcome reporting, and other issues relating to bias [61]. The protocol was registered on PROSPERO (registration number: CRD42024537859).
Regarding statistical analysis, categorical variables were compared using a Chi-square test and presented as frequency and percentages, while continuous variables were compared with an independent t-test and paired t-test and presented as the mean ± standard deviation (SD). A p value less than 0.05 is considered statistically significant.

3. Results

A total of 247 studies were initially identified after querying electronic databases and manual searching. After the removal of 23 duplicates, we screened the titles and abstracts of 224 studies. After the exclusion of 130 records, 94 full-text articles were identified and assessed for eligibility, resulting in the selection of 48 RCTs. Finally, after the exclusion of 16 RCTs (see Supplementary Table S1 for the reasons for their exclusion), 32 RCTs [7,8,10,12,13,14,15,16,17,18,20,21,22,25,26,28,30,31,32,34,35,37,38,39,41,43,45,46,47,48,49,51] were included in the systematic review. The study selection process is summarized in the PRISMA flow diagram in Figure 1. The main characteristics of the studies included in the systematic review are summarized in Table 1. All studies included in this analysis involved patients hospitalized for COVID-19 of various degrees of severity, with the exception of two RCTs [16,47] which recruited critically ill patients admitted to an intensive care unit (ICU). All but two RCTs [31,49] began recruitment in 2020, during the first or second pandemic wave. In 10 of the 32 RCTs (31.2%), the number of cases/controls enrolled was lower than that planned by the study design. The reasons reported by the authors for early study termination were futility at interim analysis (three RCTs) [13,14,43], the EUA from FDA (one RCT) [10], the presence of high-titer nAbs in recipients at admission before CCP transfusion (one RCT) [15], vaccination coverage and the availability of anti-SARS-CoV-2 monoclonal antibodies (mAbs) (one RCT) [49], and slow recruitment due to the trial taking place during the interpandemic period (four RCTs) [21,26,31,32]. For 19 of the 32 (59.4%) selected RCTs, the primary outcome also included mortality rate, with the primary endpoint being reached in 6 studies (18.8%). The 28-day mortality rates differed widely among the studies, with the highest rate being recorded in the CONFIDENT [16] (35.4% in CCP group and 45.0% in control group) and COPLA-II [20] (53.2% in CCP group and 46.8% in control group) trials and the lowest rate being recorded in the ConPlas [17] (3.9% in CCP group and 8.2% in control group) and TSUNAMI [51] (6.1% in CCP group and 7.9% in control group) studies. Two studies [21,49] did not report deaths in either the treatment or control arm. Among the 28 RCTs reporting deaths as a primary or secondary outcome, two RCTs [16,34] (7.1%) reported a 28-day mortality rate significantly lower in CCP-treated patients than controls. Regarding sample size estimation, the great majority of RCTs were designed with a statistical power of 80% and a 5% level of significance. Wide inter-study variation in the expected relative difference in the primary outcome between the CCP treatment and control groups was observed, ranging from 25% to 50%. This heterogeneity among the RCTs was also evident when the expected absolute improvement in the primary outcome of CCP-treated patients was considered, ranging from 15% to 50%.
A statistically significant low in the median expected absolute difference was observed in studies with a favorable outcome [21,28] compared to those with an unfavorable outcome [7,12,15,18,22,38,39,45,46] (20.0% versus 33.9%, p = 0.04).
Regarding ROB analysis in included studies, we assessed seven studies with a low risk of bias in all the items considered (see Supplementary Figure S2). The remaining 25 studies were judged to have a high or unclear risk of bias for one or more domains. Nearly 70% of studies were open-label studies; hence, they were at risk of performance or detection bias (in studies with unmasked evaluators).

4. Discussion

Since the publication of the first RCTs on the use of CCP, it has been evident that the clinical effect of CCP depends on several factors, with the most important one being the phase of the viral infection (the earlier the plasma is transfused, the more effective the CCP treatment is) and its content in nAbs (the more nAbs there are in the CCP, the more effective it is). The latter factor matches the serologic status of CCP recipients: patients with a reduced or absent antibody response against SARS-CoV-2, such as immunocompromised patients, respond better to high-titer CCP therapy [55]. In addition to the timing and dosing of CCP, there are other key determining factors of CCP effectiveness, among which the study design must be mentioned, in particular the sample size estimation [62,63]. Sample size calculation is an essential component of a study protocol. The ex ante determination of the minimum number of observations that have to be recorded is essential in order to detect a supposed treatment effect, and thus, it is closely related to the success or the failure of the trial [64]. In turn, the calculation of the sample size of a new trial depends on the expected effectiveness of the treatment compared to the control. The greater the difference observed, the smaller the number of events to be collected. In other words, the sample size needed to assess the treatment effectiveness is higher when the real treatment effect is lower (Supplementary Table S2 and Supplementary Figure S1). Generally, RCTs with a small sample size are easy to conduct and economically sustainable, particularly for independent, non-sponsored trials, and, thus, they are usually preferred over those with a very large sample size, which are expensive and time consuming. By contrast, small-size RCTs are prone to having low statistical power and promote misleading inferences, while large-size RCTs are generally far more efficient in producing consistent evidence [65]. The a priori estimation of a given difference in the efficacy between an intervention and comparator during the planning of a study design is usually based on previous trials on the same topic, but, unfortunately, this is not possible for a new disease. As COVID-19 was a new illness, the investigators could not design RCTs using prior experience (the majority of the RCTs started concomitantly in 2020 during the first or second pandemic wave), and thus, they utilized results regarding CCP efficacy from trials conducted in previous coronavirus epidemics, such as the SARS and MERS epidemics, or results from uncontrolled SARS-CoV-2 studies. Thus, as shown by the analyses of the sample sizes of 32 RCTs, many estimated a 30 to 50% a priori relative reduction (or improvement) in the primary outcome by the intervention (CCP) to calculate the number of hospitalized COVID-19 patients to enroll. This approach was, however, wrong for at least two reasons: first, it became evident immediately after the outbreak of the pandemic that the COVID-19 pandemic had a different degree of severity compared to the two previous coronavirus epidemics. Furthermore, studies conducted (and published) in the early phase of the COVID-19 pandemic clearly showed that a “Lazarus effect” was not possible with either CCP or other antibody-based or small-molecule antivirals, meaning that a drug could be considered effective if it led to an improvement in the primary outcome in a range between 10% and 20% [57]. In fact, the closest historical account of the use of CCP in a pandemic was the use of convalescent serum in the 1918 influenza pandemic, where a favorable size effect of 20% was estimated from retrospective analysis [66]. A posteriori, this was also confirmed to be true for CCP, as documented by the most recent literature review, which showed an overall 13% reduced risk of mortality of CCP compared with standard-of-care treatment or placebo in hospitalized COVID-19 patients [56]. This issue was further complicated by the wide heterogeneity in the methodologies used by the different RCTs for sample size estimation (relative or absolute difference and odds ratios), hampering among-study comparisons.
In addition to this methodological heterogeneity, COVID-19 presented challenges that are not usually encountered in RCTs, including the fact that the efficacy of antibody therapy varied with length of illness and the rapid progression of the underlying disease. For example, the efficacy of CCP in preventing the progression of disease to hospitalization exceeds that of monoclonal antibodies when given in the first 5 days of infection [54], but CCP has little or no efficacy when administered after the third day of hospitalization [4], whereas the overall survival benefit associated with CCP, considering over thirty RCTs, was 13%, and the estimated efficacy in reducing mortality when administered in the first three days of hospitalization using high-titer plasma was 37% [56]. Given that the efficacy of CCP diminishes rapidly with time, the inevitable delays associated with enrollment, randomization, and CCP administration in RCTs served to further reduce the likelihood of finding a favorable effect. Hence, the rapid progression of COVID-19, combined with the reduced efficacy of CCP as a function of time, significantly increased the heterogeneity of patients enrolled in RCTs, which further reduced the likelihood of finding statistically significant effects given the sample sizes studied.
Approximately one third of the RCTs evaluated in the present systematic review were terminated prematurely for a series of reasons, but no company-sponsored RCTs of antibody-based or small molecule antivirals were terminated prematurely. Among the reasons for premature termination, the most relevant reason is problems regarding patient enrolment between the pandemic waves or because of the EUA of CCP granted by the FDA, both of which deprived the US-based RCTs on CCP of many patients. Despite this, it is noteworthy that at least two RCTs including hospitalized patients were completed in the USA [18,36], showing that it was possible to test CCP under EUA. It is noteworthy that many CCP RCTs did not have commercial sponsors and, thus, in terms of patient recruitment, they did not have the financial incentives that are often associated with pharmaceutical trials. Likewise, the cessation of some RCTs at interim analysis for futility could have been due to the vicious circle created by the discrepancy between the virtual (expected) and the real (observed) treatment effect. Adding to these hurdles, the enrolment of patients in CCP trials often made them ineligible to participate in other RCTs for other COVID-19 therapies supported by pharmaceutical companies that usually provide payment for each participant, thus creating further disincentives for continued recruitment in CCP RCTs during the highs and lows of the SARS-CoV-2 waves.
Therefore, such RCTs could not have sufficient statistical power for two reasons, i.e., reduced enrolment in the context of an already reduced sample size that had been calculated by overestimating the CCP treatment effect. In support of the latter argument, we observed that the expected absolute difference between intervention and comparator in the primary outcome was significantly lower in favorable versus unfavorable studies. Furthermore, it is noteworthy that an industry-led double-blinded phase 3 RCT testing the efficacy of mAb tixagevimab–cilgavimab versus placebo in hospitalized COVID-19 patients showed benefits for the mAb combination, in which the design assumed a 20% effect (power 90%, 5% significance level) for sample size estimation, and the expected recruitment target was fully achieved [67].
In conclusion, the results of our systematic review, which was performed on 32 RCTs, clearly underline the important role of sample size calculation in the design of different studies evaluating CCP efficacy in hospitalized COVID-19 patients. From our systematic analysis of the literature on this topic, we have found that the sample size estimate is a key determinant of treatment effectiveness. Indeed, it is a fact that most RCTs lack statistical power due to an overlooked size effect that could negatively influence their results and restrict them from reaching enough events, in both cases and controls, to correctly evaluate the effect of CCP treatment. But what would have been the results of these studies if they had set their size effect at a lower (below 20%), and more realistic, difference level? At this time, it is not possible (and not methodologically correct) to try to answer to this question ex post. Perhaps, however, if this had happened, the history of the results of many RCTs and of the clinical use of CCP worldwide during the pandemic would have turned out differently.

Supplementary Materials

The following supporting information can be downloaded at: https://0-www-mdpi-com.brum.beds.ac.uk/article/10.3390/life14070792/s1, Supplementary Table S1. Randomized controlled trials excluded from the analysis. Supplementary Table S2. Sample size estimation. Supplementary Figure S1. The non-linear relationship between expected effected size and necessary recruitment in each study arm. Supplementary Figure S2. Risk of Bias (ROB) analysis of the included studies. PRISMA checklist for this study. Ref. [68] is Supplementary Materials file.

Author Contributions

M.F. conceived the study and wrote the first draft. C.M. performed statistical analyses. D.F. and A.C. critically revised the manuscript. All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

This manuscript generated no novel dataset.

Conflicts of Interest

A.C.—Scientific Advisory Board of Sabtherapeutics (cow-derived human immunoglobulin COVID-19 treatment and other infectious diseases) and Ortho Diagnostics Speakers Bureau. The other authors have no conflicts of interest to disclose related to this manuscript.

References

  1. Shen, C.; Wang, Z.; Zhao, F.; Yang, Y.; Li, J.; Yuan, J.; Wang, F.; Li, D.; Yang, M.; Xing, L.; et al. Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma. JAMA 2020, 323, 1582–1589. [Google Scholar] [CrossRef] [PubMed]
  2. Perotti, C.; Baldanti, F.; Bruno, R.; Del Fante, C.; Seminari, E.; Casari, S.; Percivalle, E.; Glingani, C.; Musella, V.; Belliato, M.; et al. Mortality reduction in 46 severe Covid-19 patients treated with hyperimmune plasma. A proof of concept single arm multicenter trial. Haematologica 2020, 105, 2834–2840. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
  3. Senefeld, J.W.; Johnson, P.W.; Kunze, K.L.; Bloch, E.M.; van Helmond, N.; Golafshar, M.A.; Klassen, S.A.; Klompas, A.M.; Sexton, M.A.; Diaz Soto, J.C.; et al. Access to and safety of COVID-19 convalescent plasma in the United States Expanded Access Program: A national registry study. PLoS Med. 2021, 18, e1003872. [Google Scholar] [CrossRef] [PubMed]
  4. Joyner, M.J.; Carter, R.E.; Senefeld, J.W.; Klassen, S.A.; Mills, J.R.; Johnson, P.W.; Theel, E.S.; Wiggins, C.C.; Bruno, K.A.; Klompas, A.M.; et al. Convalescent Plasma Antibody Levels and the Risk of Death from Covid-19. N. Engl. J. Med. 2021, 384, 1015–1027. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
  5. Bloch, E.M.; Shoham, S.; Casadevall, A.; Sachais, B.S.; Shaz, B.; Winters, J.L.; van Buskirk, C.; Grossman, B.J.; Joyner, M.; Henderson, J.P.; et al. Deployment of convalescent plasma for the prevention and treatment of COVID-19. J. Clin. Investig. 2020, 130, 2757–2765. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
  6. AlQahtani, M.; Abdulrahman, A.; Almadani, A.; Alali, S.Y.; Al Zamrooni, A.M.; Hejab, A.H.; Conroy, R.M.; Wasif, P.; Otoom, S.; Atkin, S.L.; et al. Randomized controlled trial of convalescent plasma therapy against standard therapy in patients with severe COVID-19 disease. Sci. Rep. 2021, 11, 9927. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
  7. Balcells, M.E.; Rojas, L.; Le Corre, N.; Martínez-Valdebenito, C.; Ceballos, M.E.; Ferrés, M.; Chang, M.; Vizcaya, C.; Mondaca, S.; Huete, Á.; et al. Early versus deferred anti-SARS-CoV-2 convalescent plasma in patients admitted for COVID-19: A randomized phase II clinical trial. PLoS Med. 2021, 18, e1003415. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
  8. Baldeón, M.E.; Maldonado, A.; Ochoa-Andrade, M.; Largo, C.; Pesantez, M.; Herdoiza, M.; Granja, G.; Bonifaz, M.; Espejo, H.; Mora, F.; et al. Effect of convalescent plasma as complementary treatment in patients with moderate COVID-19 infection. Transfus. Med. 2022, 32, 153–161. [Google Scholar] [CrossRef] [PubMed]
  9. Beltran Gonzalez, J.L.; Gonzalez Gamez, M.; Mendoza Enciso, E.A.; Esparza Maldonado, R.J.; Hernandez Palacios, D.; Duenas Campos, S.; Ovalle Robles, I.; Macias Guzman, M.J.; Garcia Diaz, A.L.; Gutierrez-Pena, C.M.; et al. Efficacy and safety of convalescent plasma and intravenous immunoglobulin in critically ill COVID-19 patients. A controlled clinical trial. medRxiv 2021. [Google Scholar] [CrossRef]
  10. Bennett-Guerrero, E.; Romeiser, J.L.; Talbot, L.R.; Ahmed, T.; Mamone, L.J.; Singht, S.M.; Hearing, J.C.; Salman, H.; Holiprosad, D.D.; Freedenberg, A.T.; et al. Severe Acute Respiratory Syndrome Coronavirus 2 Convalescent Plasma Versus Standard Plasma in Coronavirus Disease 2019 Infected Hospitalized Patients in New York: A Double-Blind Randomized Trial. Crit. Care Med. 2021, 49, 1015–1025. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
  11. Korley, F.K.; Durkalski-Mauldin, V.; Yeatts, S.D.; Schulman, K.; Davenport, R.D.; Dumont, L.J.; El Kassar, N.; Foster, L.D.; Hah, J.M.; Jaiswal, S.; et al. Early Convalescent Plasma for High-Risk Outpatients with COVID-19. N. Engl. J. Med. 2021, 385, 1951–1960. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
  12. Körper, S.; Weiss, M.; Zickler, D.; Wiesmann, T.; Zacharowski, K.; Corman, V.M.; Grüner, B.; Ernst, L.; Spieth, P.; Lepper, P.M.; et al. Results of the CAPSID randomized trial for high-dose convalescent plasma in patients with severe COVID-19. J. Clin. Investig. 2021, 131, e152264. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
  13. Thorlacius-Ussing, L.; Brooks, P.T.; Nielsen, H.; Jensen, B.A.; Wiese, L.; Saekmose, S.G.; Johnsen, S.; Gybel-Brask, M.; Johansen, I.S.; Topholm Bruun, M.; et al. A randomized placebo-controlled trial of convalescent plasma for adults hospitalized with COVID-19 pneumonia. Sci. Rep. 2022, 12, 16385. [Google Scholar] [CrossRef] [PubMed]
  14. Bégin, P.; Callum, J.; Jamula, E.; Cook, R.; Heddle, N.M.; Tinmouth, A.; Zeller, M.P.; Beaudoin-Bussières, G.; Amorim, L.; Bazin, R.; et al. Convalescent plasma for hospitalized patients with COVID-19: An open-label, randomized controlled trial. Nat. Med. 2021, 27, 2012–2024, Erratum in Nat. Med. 2022, 28, 212. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
  15. Gharbharan, A.; Jordans, C.C.E.; GeurtsvanKessel, C.; den Hollander, J.G.; Karim, F.; Mollema, F.P.N.; Stalenhoef-Scukken, J.E.; Dofferhoff, A.; Ludwig, I.; Koster, A.; et al. Effects of potent neutralizing antibodies from convalescent plasma in patients hospitalized for severe SARS-CoV-2 infection. Nat. Commun. 2021, 12, 3189. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
  16. Misset, B.; Piagnerelli, M.; Hoste, E.; Dardenne, N.; Grimaldi, D.; Michaux, I.; De Waele, E.; Dumoulin, A.; Jorens, P.G.; van der Hauwaert, E.; et al. Convalescent Plasma for Covid-19-Induced ARDS in Mechanically Ventilated Patients. N. Engl. J. Med. 2023, 389, 1590–1600. [Google Scholar] [CrossRef] [PubMed]
  17. Avendaño-Solá, C.; Ramos-Martínez, A.; Muñez-Rubio, E.; Ruiz-Antoran, B.; Malo de Molina, R.; Torres, F.; Fernandez-Cruz, A.; Calderon-Parra, J.; Payeares-Herrera, C.; Diaz De Santiago, A.; et al. A multicenter randomized open-label clinical trial for convalescent plasma in patients hospitalized with COVID-19 pneumonia. J. Clin. Investig. 2021, 131, e152740. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
  18. Ortigoza, M.B.; Yoon, H.; Goldfeld, K.S.; Troxel, A.B.; Daily, J.P.; Wu, Y.; Li, Y.; Wu, D.; Cobb, G.F.; Baptiste, G.; et al. Efficacy and Safety of COVID-19 Convalescent Plasma in Hospitalized Patients: A Randomized Clinical Trial. JAMA Intern. Med. 2022, 182, 115–126. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
  19. Alemany, A.; Millat-Martinez, P.; Corbacho-Monné, M.; Malchair, P.; Ouchi, D.; Ruiz-Comellas, A.; Ramírez-Morros, A.; Rodríguez Codina, J.; Amado Simon, R.; Videla, S.; et al. High-titre methylene blue-treated convalescent plasma as an early treatment for outpatients with COVID-19: A randomised, placebo-controlled trial. Lancet Respir. Med. 2022, 10, 278–288. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
  20. Holm, K.; Lundgren, M.N.; Kjeldsen-Kragh, J.; Ljungquist, O.; Böttiger, B.; Wikén, C.; Öberg, J.; Fernström, N.; Rosendal, E.; Överby, A.K.; et al. Convalescence plasma treatment of COVID-19: Results from a prematurely terminated randomized controlled open-label study in Southern Sweden. BMC Res. Notes 2021, 14, 440. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
  21. Bajpai, M.; Maheshwari, A.; Dogra, V.; Kumar, S.; Gupta, E.; Kale, P.; Saluja, V.; Thomas, S.S.; Trehanpati, N.; Bihari, C.; et al. Efficacy of convalescent plasma therapy in the patient with COVID-19: A randomised control trial (COPLA-II trial). BMJ Open 2022, 12, e055189. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
  22. Bargay-Lleonart, J.; Sarubbo, F.; Arrizabalaga, M.; Guerra, J.M.; Borras, J.; El Hajii, K.; Flexas, M.; Perales, J.; Fernandez-Baca, V.; Gallegos, C.; et al. Reinforcement of the Standard Therapy with Two Infusions of Convalescent Plasma for Patients with COVID-19: A Randomized Clinical Trial. J. Clin. Med. 2022, 11, 3039. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
  23. Lacombe, K.; Hueso, T.; Porcher, R.; Mekinian, A.; Chiarabini, T.; Georgin-Lavialle, S.; Ader, F.; Saison, J.; Martin-Blondel, G.; De Castro, N.; et al. Use of covid-19 convalescent plasma to treat patients admitted to hospital for covid-19 with or without underlying immunodeficiency: Open label, randomised clinical trial. BMJ Med. 2023, 2, e000427. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
  24. Gharbharan, A.; Jordans, C.; Zwaginga, L.; Papageorgiou, G.; van Geloven, N.; van Wijngaarden, P.; den Hollander, J.; Karim, F.; van Leeuwen-Segarceanu, E.; Soetekouw, R.; et al. Outpatient convalescent plasma therapy for high-risk patients with early COVID-19: A randomized placebo-controlled trial. Clin. Microbiol. Infect. 2023, 29, 208–214. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
  25. Bartelt, L.A.; Markmann, A.J.; Nelson, B.; Keys, J.; Root, H.; Henderson, H.I.; Kuruc, J.A.; Baker, C.; Bhowmik, D.R.; Hou, Y.J.; et al. Outcomes of Convalescent Plasma with Defined High versus Lower Neutralizing Antibody Titers against SARS-CoV-2 among Hospitalized Patients: CoronaVirus Inactivating Plasma (CoVIP) Study. mBio 2022, 13, e0175122. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
  26. Devos, T.; Van Thillo, Q.; Compernolle, V.; Najdovski, T.; Romano, M.; Dauby, N.; Jadot, L.; Leys, M.; Maillart, E.; Loof, S.; et al. Early high antibody titre convalescent plasma for hospitalised COVID-19 patients: DAWn-plasma. Eur. Respir J. 2022, 59, 2101724. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
  27. Denkinger, C.M.; Janssen, M.; Schäkel, U.; Gall, J.; Leo, A.; Stelmach, P.; Weber, S.F.; Krisam, J.; Baumann, L.; Stermann, J.; et al. Anti-SARS-CoV-2 antibody-containing plasma improves outcome in patients with hematologic or solid cancer and severe COVID-19: A randomized clinical trial. Nat. Cancer 2023, 4, 96–107. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
  28. De Santis, G.C.; Oliveira, L.C.; Garibaldi, P.M.M.; Almado, C.E.L.; Croda, J.; Arcanjo, G.G.A.; Oliveira, É.A.F.; Tonacio, A.C.; Langhi, D.M., Jr.; Bordin, J.O.; et al. High-Dose Convalescent Plasma for Treatment of Severe COVID-19. Emerg. Infect. Dis. 2022, 28, 548–555. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
  29. Hamdy Salman, O.; Ail Mohamed, H.S. Efficacy and safety of transfusing plasma from COVID-19 survivors to COVID-19 victims with severe illness. A double-blinded controlled preliminary study. Egypt. J. Anaesth. 2020, 36, 264–272. [Google Scholar] [CrossRef]
  30. Irawan, C.; Rumende, C.M.; Sukrisman, L.; Pitoyo, C.W.; Suwarto, S.; Susilo, A.; Mulansari, N.A.; Harahap, A.T.; Priantono, D.; Syafitri, R.; et al. Efficacy of COVID convalescent plasma therapy in hospitalized moderate coronavirus disease 2019 patients. J. Infect. Dev. Ctries 2023, 17, 43–51. [Google Scholar] [CrossRef] [PubMed]
  31. Kirenga, B.; Byakika-Kibwika, P.; Muttamba, W.; Kayongo, A.; Loryndah, N.O.; Mugenyi, L.; Kiwanuka, N.; Lusiba, J.; Atukunda, A.; Mugume, R.; et al. Efficacy of convalescent plasma for treatment of COVID-19 in Uganda. BMJ Open Respir. Res. 2021, 8, e001017. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
  32. Khawaja, T.; Kajova, M.; Levonen, I.; Pietilä, J.P.; Välimaa, H.; Paajanen, J.; Pakkanen, S.H.; Patjas, A.; Montonen, R.; Miettinen, S.; et al. Double-blinded, randomised, placebo-controlled trial of convalescent plasma for COVID-19: Analyses by neutralising antibodies homologous to donors’ variants. Infect. Dis. 2024, 56, 423–433. [Google Scholar] [CrossRef] [PubMed]
  33. Li, L.; Zhang, W.; Hu, Y.; Tong, X.; Zheng, S.; Yang, J.; Kong, Y.; Ren, L.; Wei, Q.; Mei, H.; et al. Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients with Severe and Life-threatening COVID-19: A Randomized Clinical Trial. JAMA 2020, 324, 460–470. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
  34. Libster, R.; Pérez Marc, G.; Wappner, D.; Coviello, S.; Bianchi, A.; Braem, V.; Esteban, I.; Caballero, M.T.; Wood, C.; Berrueta, M.; et al. Early High-Titer Plasma Therapy to Prevent Severe COVID-19 in Older Adults. N. Engl. J. Med. 2021, 384, 610–618. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
  35. O’Donnell, M.R.; Grinsztejn, B.; Cummings, M.J.; Justman, J.E.; Lamb, M.R.; Eckhardt, C.M.; Philip, N.M.; Cheung, Y.K.; Gupta, V.; João, E.; et al. A randomized double-blind controlled trial of convalescent plasma in adults with severe COVID-19. J. Clin. Investig. 2021, 131, e150646. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
  36. Self, W.H.; Wheeler, A.P.; Stewart, T.G.; Schrager, H.; Mallada, J.; Thomas, C.B.; Cataldo, V.D.; O’Neal, H.R., Jr.; Shapiro, N.I.; Higgins, C.; et al. Neutralizing COVID-19 Convalescent Plasma in Adults Hospitalized With COVID-19: A Blinded, Randomized, Placebo-Controlled Trial. Chest 2022, 162, 982–994. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
  37. Bar, K.J.; Shaw, P.A.; Choi, G.H.; Aqui, N.; Fesnak, A.; Yang, J.B.; Soto-Calderon, H.; Grajales, L.; Starr, J.; Andronov, M.; et al. A randomized controlled study of convalescent plasma for individuals hospitalized with COVID-19 pneumonia. J. Clin. Investig. 2021, 131, e155114. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
  38. Agarwal, A.; Mukherjee, A.; Kumar, G.; Chatterjee, P.; Bhatnagar, T.; Malhotra, P.; PLACID Trial Collaborators. Convalescent plasma in the management of moderate COVID-19 in adults in India: Open label phase II multicentre randomised controlled trial (PLACID Trial). BMJ 2020, 371, m3939, Erratum in BMJ 2020, 371, m4232. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
  39. Manzini, P.M.; Ciccone, G.; De Rosa, F.G.; Cavallo, R.; Ghisetti, V.; D’Antico, S.; Galassi, C.; Saccona, F.; Castiglione, A.; Birocco, N.; et al. Convalescent or standard plasma versus standard of care in the treatment of COVID-19 patients with respiratory impairment: Short and long-term effects. A three-arm randomized controlled clinical trial. BMC Infect. Dis. 2022, 22, 879. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
  40. Sekine, L.; Arns, B.; Fabro, B.R.; Cipolatt, M.M.; Machado, R.R.G.; Durigon, E.L.; Parolo, E.; Pellegrini, J.A.S.; Viana, M.V.; Schwarz, P.; et al. Convalescent plasma for COVID-19 in hospitalised patients: An open-label, randomised clinical trial. Eur. Respir J. 2022, 59, 2101471. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
  41. Siripongboonsitti, T.; Nontawong, N.; Tawinprai, K.; Suptawiwat, O.; Soonklang, K.; Poovorawan, Y.; Mahanonda, N. Efficacy of combined COVID-19 convalescent plasma with oral RNA-dependent RNA polymerase inhibitor treatment versus neutralizing monoclonal antibody therapy in COVID-19 outpatients: A multi-center, non-inferiority, open-label randomized controlled trial (PlasMab). Microbiol Spectr. 2023, 11, e0325723. [Google Scholar] [CrossRef] [PubMed]
  42. Simonovich, V.A.; Burgos Pratx, L.D.; Scibona, P.; Beruto, M.V.; Vallone, M.G.; Vázquez, C.; Savoy, N.; Giunta, D.H.; Pérez, L.G.; Sánchez, M.D.L.; et al. A Randomized Trial of Convalescent Plasma in Covid-19 Severe Pneumonia. N. Engl. J. Med. 2021, 384, 619–629. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
  43. Pouladzadeh, M.; Safdarian, M.; Eshghi, P.; Abolghasemi, H.; Ghorbani Bavani, A.; Sheibani, B.; Mroadi Chogahakabodi, P.; Feghhi, A.; Ghafourian Boroujerdnia, M.; Forouzan, A.; et al. A randomized clinical trial evaluating the immunomodulatory effect of convalescent plasma on COVID-19-related cytokine storm. Intern. Emerg. Med. 2021, 16, 2181–2191. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
  44. van den Berg, K.; Glatt, T.N.; Vermeulen, M.; Little, F.; Swanevelder, R.; Barrett, C.; Court, R.; Bremer, M.; Nyoni, C.; Swarts, A.; et al. Convalescent plasma in the treatment of moderate to severe COVID-19 pneumonia: A randomized controlled trial (PROTECT-Patient Trial). Sci. Rep. 2022, 12, 2552. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
  45. Rasheed, A.M.; Fatak, D.F.; Hashim, H.A.; Maulood, M.F.; Kabah, K.K.; Almusawi, Y.A.; Abdulamir, A.S. The therapeutic potential of convalescent plasma therapy on treating critically-ill COVID-19 patients residing in respiratory care units in hospitals in Baghdad, Iraq. Infez. Med. 2020, 28, 357–366. [Google Scholar] [PubMed]
  46. Ray, Y.; Paul, S.R.; Bandopadhyay, P.; D’Rozario, R.; Sarif, J.; Raychaudhuri, D.; Bhowmik, D.; Lahiri, A.; Vasudevan, J.S.; Maurya, R.; et al. A phase 2 single center open label randomised control trial for convalescent plasma therapy in patients with severe COVID-19. Nat. Commun. 2022, 13, 383. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
  47. RECOVERY Collaborative Group. Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): A randomised controlled, open-label, platform trial. Lancet 2021, 397, 2049–2059. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
  48. Writing Committee for the REMAP-CAP Investigators; Estcourt, L.J.; Turgeon, A.F.; McQuilten, Z.K.; McVerry, B.J.; Al-Beidh, F.; Annane, D.; Arabi, Y.M.; Arnold, D.M.; Beane, A.; et al. Effect of Convalescent Plasma on Organ Support-Free Days in Critically Ill Patients With COVID-19: A Randomized Clinical Trial. JAMA 2021, 326, 1690–1702. [Google Scholar] [CrossRef] [PubMed]
  49. Rojas, M.; Rodríguez, Y.; Hernández, J.C.; Díaz-Coronado, J.C.; Vergara, J.A.D.; Vélez, V.P.; Mancilla, J.P.; Araujo, I.; Yepes, J.T.; Ricaurte, O.B.; et al. Safety and efficacy of convalescent plasma for severe COVID-19: A randomized, single blinded, parallel, controlled clinical study. BMC Infect. Dis. 2022, 22, 575. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
  50. Saito, S.; Kutsuna, S.; Akifumi, I.; Hase, R.; Oda, R.; Terada, J.; Shimizu, Y.; Uemura, Y.; Takamatsu, Y.; Yasuhara, A.; et al. Efficacy of convalescent plasma therapy for COVID-19 in Japan: An open-label, randomized, controlled trial. J. Infect. Chemother. 2023, 29, 869–874. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
  51. Sullivan, D.J.; Gebo, K.A.; Shoham, S.; Bloch, E.M.; Lau, B.; Shenoy, A.G.; Mosnaim, G.S.; Gniadek, T.J.; Fukuta, Y.; Patel, B.; et al. Early Outpatient Treatment for Covid-19 with Convalescent Plasma. N. Engl. J. Med. 2022, 386, 1700–1711. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
  52. Menichetti, F.; Popoli, P.; Puopolo, M.; Spila Alegiani, S.; Tiseo, G.; Bartoloni, A.; De Socio, G.V.; Luchi, S.; Blanc, P.; Puoti, M.; et al. Effect of High-Titer Convalescent Plasma on Progression to Severe Respiratory Failure or Death in Hospitalized Patients With COVID-19 Pneumonia: A Randomized Clinical Trial. JAMA Netw. Open 2021, 4, e2136246, Erratum in JAMA Netw. Open 2022, 5, e2146944. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
  53. Ventura-Enríquez, Y.; Cabello-Gutiérrez, C.; Pérez-Calatayud, Á.A.; Cortina-De La Rosa, E.; Fareli-Gonzale, C.J.; Castillo-Juarez, P.; Pena-Perez Carlos, A.; Zavaleta-Martinez, E.O.; Diaz-Padilla, E.; Murrieta, S.; et al. Convalescent Plasma to Treat COVID-19: A Two-Center, Randomized, Double-Blind Clinical Trial. Life 2022, 12, 1767. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
  54. Senefeld, J.W.; Franchini, M.; Mengoli, C.; Cruciani, M.; Zani, M.; Gorman, E.K.; Focosi, D.; Casadevall, A.; Joyner, M.J. COVID-19 Convalescent Plasma for the Treatment of Immunocompromised Patients: A Systematic Review and Meta-analysis. JAMA Netw. Open 2023, 6, e2250647. [Google Scholar] [CrossRef] [PubMed]
  55. Sullivan, D.J.; Focosi, D.; Hanley, D.F.; Cruciani, M.; Franchini, M.; Ou, J.; Casadevall, A.; Paneth, N. Outpatient randomized controlled trials to reduce COVID-19 hospitalization: Systematic review and meta-analysis. J. Med. Virol. 2023, 95, e29310. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
  56. Focosi, D.; Franchini, M. COVID-19 convalescent plasma therapy: Hit fast, hit hard! Vox Sang 2021, 116, 935–942. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
  57. Senefeld, J.W.; Gorman, E.K.; Johnson, P.W.; Moir, M.E.; Klassen, S.A.; Carter, R.E.; Paneth, N.S.; Sullivan, D.J.; Morkeberg, O.H.; Wright, R.S.; et al. Rates Among Hospitalized Patients With COVID-19 Treated with Convalescent Plasma: A Systematic Review and Meta-Analysis. Mayo Clin. Proc. Innov. Qual. Outcomes 2023, 7, 499–513. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
  58. Iannizzi, C.; Chai, K.L.; Piechotta, V.; Valk, S.J.; Kimber, C.; Monsef, I.; Wood, E.M.; Lamikanra, A.A.; Roberts, D.J.; McQuilten, Z.; et al. Convalescent plasma for people with COVID-19: A living systematic review. Cochrane Database Syst. Rev. 2023, 5, CD013600. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
  59. Franchini, M.; Liumbruno, G.M.; Piacentini, G.; Glingani, C.; Zaffanello, M. The Three Pillars of COVID-19 Convalescent Plasma Therapy. Life 2021, 11, 354. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
  60. Zheng, K.; Liao, G.; Lalu, M.M.; Tinmouth, A.; Fergusson, D.A.; Allan, D.S. A Scoping Review of Registered Clinical Trials of Convalescent Plasma for COVID-19 and a Framework for Accelerated Synthesis of Trial Evidence (FAST Evidence). Transfus. Med. Rev. 2020, 34, 158–164. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
  61. Schünemann, H.J.; Oxman, A.D.; Higgins, J.P.; Vist, G.E.; Glasziou, P.; Guyatt, G.H. Chapter 11: Presenting results and ‘Summary of findings’ tables. In Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0; (updated March 2011); Higgins, J.P., Green, S., Eds.; The Cochrane Collaboration: London, UK, 2011; Available online: https://handbook-5-1.cochrane.org/ (accessed on 19 June 2024).
  62. Nakagawa, S.; Lagisz, M.; Yang, Y.; Drobniak, S.M. Finding the right power balance: Better study design and collaboration can reduce dependence on statistical power. PLoS Biol. 2024, 22, e3002423. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
  63. Kadam, P.; Bhalerao, S. Sample size calculation. Int. J. Ayurveda Res. 2010, 1, 55–57. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
  64. Wang, X.; Ji, X. Sample Size Estimation in Clinical Research: From Randomized Controlled Trials to Observational Studies. Chest 2020, 158, S12–S20. [Google Scholar] [CrossRef] [PubMed]
  65. Janiaud, P.; Hemkens, L.G.; Ioannidis, J.P.A. Challenges and Lessons Learned From COVID-19 Trials: Should We Be Doing Clinical Trials Differently? Can. J. Cardiol. 2021, 37, 1353–1364. [Google Scholar] [CrossRef] [PubMed]
  66. Luke, T.C.; Kilbane, E.M.; Jackson, J.L.; Hoffman, S.L. Meta-analysis: Convalescent blood products for Spanish influenza pneumonia: A future H5N1 treatment? Ann. Intern. Med. 2006, 145, 599–609. [Google Scholar] [CrossRef] [PubMed]
  67. ACTIV-3–Therapeutics for Inpatients with COVID-19 (TICO) Study Group. Tixagevimab-cilgavimab for treatment of patients hospitalised with COVID-19: A randomised, double-blind, phase 3 trial. Lancet Respir. Med. 2022, 10, 972–984, Erratum in Lancet Respir. Med. 2022. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
  68. Page, M.J.; McKenzie, J.E.; Bossuyt, P.M.; Boutron, I.; Hoffmann, T.C.; Mulrow, C.D.; Shamseer, L.; Tetzlaff, J.M.; Akl, E.A.; Brennan, S.E.; et al. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews Systematic reviews and Meta-Analyses. BMJ 2021, 372, n71. [Google Scholar] [CrossRef] [PubMed]
Life 14 00792 g001
Figure 1. Flow chart of study inclusion process.
Figure 1. Flow chart of study inclusion process.
Life 14 00792 g001
Table 1. Characteristics of the 32 RCTs included in the analysis.
Table 1. Characteristics of the 32 RCTs included in the analysis.
Study, Year
[ref.] NCT		Study Design Recruitment
Start
(mm/dd/yy)		Sample Size EstimationCases/ControlsEarly Termination
(Reason)		Primary Outcome28-Day Mortality
Effect Size 1PowerCLExpectedActualEndpointReached
Balcells, 2021 [7]Open-label RCT including hospitalized COVID-19 patients 05/10/2020AD: 35%80%95%29 early CCP + ST/29 late CCP + ST28 early CCP + ST/30 late CCP + STNoComposite of mechanical ventilation; hospitalization for >14 days or deathNoEarly CCP: 5/28 (17.9%)
Late CCP: 2/30 (6.7%)
P = 0.25
Baldeon, 2021 [8]Double-blind, placebo-controlled RCT including hospitalized pts. with moderate COVID-1905/01/2020RD: 40%80%95%100 CCP/95 SP63 CCP/95 SPNoSurvival rate at 28 daysNoCCP: 11.1%
SP: 12.6%
P = NS
Bennett-Guerrero, 2021 [10]Double-blind RCT including hospitalized COVID-19 patients04/08/2020RD: 25%90%95%400 CCP/100 SP59 CCP/15 SPYes
(EUA from FDA)		Number of ventilator-free days from randomization to day 28NoCCP: 14/59 (23.7%)
SP: 4/15
P = 0.80 (26.7%)
CAPSID, 2021 [12]
NCT04433910		Open-label RCT including hospitalized patients with severe COVID-1908/30/2020AD: 30%80%95%48 CCP + ST/48 ST53 CCP + ST/52 STNoComposite outcome of survival and no longer fulfilling criteria for severe COVID-19 on day 21NoCCP + ST: 8/53 (15.1%)
ST: 14/52 (26.9%)
P = 0.16
CCAP-2, 2022 [13]
NCT04345289		Double-blind, placebo-controlled RCT including hospitalized COVID-19 pts. 06/13/2020RD: 35%80%95%353 CCP/177 PL98 CCP/46 PLYes
(futility)		Clinical status on day 14NoCCP: 12/98 (12.2%)
PL: 3/46 (6.5%)
P = NS
CONCOR-1, 2021 [14] NCT04348656Open-label RCT including hospitalized patients with COVID-1905/14/2020RD: 25%80%95%800 CCP/400 ST625 CCP/313 STYes
(futility)		Composite outcome of intubation or death by day 30NoCCP: 114/548 (20.8%)
ST: 62/303 (20.5%)
P = 0.90
ConCOVID, 2021 [15]Open-label, RCT including hospitalized patients with severe COVID-1904/08/2020AD: 50%80%95%213 CCP/213 ST43 CCP/43 STYes
(nAbs in recipients
at admission)		Overall mortality until discharge NoCCP: 6/43 (13.9%)
ST: 11/43 (25.6%)
P = NS
CONFIDENT, 2023 [16] NCT04558476Open-label RCT including mechanically ventilated COVID-19 patients09/01/2020RD: 33%80%95%250 CCP/250 ST237 CCP/238 STNo28-day mortalityYesCCP: 84/237 (35.4%)
ST: 107/238 (45.0%)
P = 0.03
ConPlas, 2021 [17]
NCT04345523		Open-label RCT including hospitalized patients with COVID-1904/04/2020RD: 50%80%95%175 CCP/175 ST179 CP/171 STNoClinical worsening at 14 daysYesCCP: 7/179 (3.9%)
ST: 14/171 (8.2%)
P = 0.11
CONTAIN COVID-19, [18] NCT04364737Open-label RCT including hospitalized patients with COVID-1904/17/2020AD
18%		80%95%463 CCP/463 PL468 CCP/473 PLNoClinical status on day 14No CCP: 59/462 (12.8%)
PL: 71/462 (15.4%)
COPLA-II, 2022 [21]
NCT04425915		Open-label, phase III RCT including severe COVID-19 patients06/14/2020RD:
25%		80%95%190 CCP + ST/190 ST200 CCP + ST/200 STNoClinical improvement measured by a two-point reduction in the ordinal scaleYesCCP + ST: 42/200 (53.2%)
ST: 37/200 (46.8%)
P = 0.62
Coplasma-2020, 2022 [22]RCT including hospitalized patients with COVID-1907/01/2020AD: 20%80%95%126 CCP/63 ST37 CCP/17 STYes
(slow recruitment)		Time for clinical improvement within 21 daysYesCCP: 0/37
ST: 0/17
CORIPLASM, 2023 [23]
NCT04345991		Open-label RCT including hospitalized COVID-19 patients04/16/2020AD: 30%97.2%NR60 CCP/60 ST60 CCP/60 STNoWHO score > 6 on day 4 and survival on day 14NoCCP: 7/60 (11.7%)
ST: 12/60 (20.0%)
P = NS
DAWn-plasma, 2021 [26]RCT including patients hospitalized for COVID-19NRRD: 50%80%95%322 CCP/161 ST320 CCP/163 STNoPatient alive without mechanical ventilation at day 15NoCCP: 8.8%
ST: 8.8%
Denkinger, 2023 [27]Open-label RCT including cancer patients hospitalized with severe COVID-1909/03/2020RD: 35%80%95%87 CCP + ST/87 ST68 CCP + ST/66 STYes
(slow recruitment) 		Time to clinical improvement of two points on a 7-point ordinal scaleYesCCP + ST: 14/68 (20.6%)
ST: 19/66 (28.8%)
P = NS
Hamdy Salman, 2020 [29]RCT including hospitalized COVID-19 pts.06/01/2020AD: 20%80%95%15 CCP + ST/15 ST15 CCP + ST/15 STNoReduction in two or more of a four-category illness severity scale over 5 daysYesNR
Kirenga, 2021 [31]
NCT04542941		RCT including hospitalized COVID-19 patients09/21/2020RD: 40%80%95%66 CCP + ST/66 ST69 CCP + ST/67 STNoViral clearance by day 28NoCCP + ST: 10/69 (14.5%)
ST: 8/67 (11.9%)
P = 0.66
Khawaja, 2024 [32]RCT including hospitalized COVID-19 pts.02/02/2021RD: 45%80%95%130 HT-CCP/130 LT-CCP/130 PL18 HT-CCP/19 LT-CCP/20 PLYes (slow recruitment)Reduction in intubation and corticosteroid support, safety.NoHT-CCP: 0/18
LT-CCP: 1/19 (5.2)
PL: 0/20
Li, 2020 [33]
ChiCTR2000029757		Open-label RCT including patients with severe or life-threatening COVID-1902/14/2020RD: 40%80%95%100 CCP + ST/100 ST52 CCP + ST/51 STYes
(slow recruitment)		Time to clinical improvement within 28 daysNoCCP + ST: 8/51 (15.7%)
ST: 12/50 (24.0%)
P = 0.30
O’Donnell, 2021 [35]Double-blind RCT including hospitalized COVID-19 pts.04/21/2020OR: 1.582%NR146 CCP/73 SP150 CCP/73 SPNoClinical status at 28 daysNoCCP 19/150
SP 18/73
P = 0.03
PassITON, 2022 [36]
NCT04362176		Double-blind, placebo-controlled RCT including hospitalized COVID-19 pts.04/28/2020OR:
≤0.73		80%95%500 CCP/500 PL487 CCP/473 PLNoClinical status at 14 days NoCCP: 89/482 (18.5%)
PL: 80/465 (17.2%)
P = NS
PLACID, 2020 [38]
CTRI/2020/04/024775		Open-label, parallel-arm, phase II RCT including hospitalized patients with moderate COVID-1904/22/2020RD: 50%80%95%226 CCP + ST/226 ST235 CCP + ST/229 STNoComposite outcome of progression to sever disease or all-cause mortality at 28 daysNoCCP + ST: 44/235 (18.7%)
ST: 41/229 (17.9%)
P = NS
PLACO COVID, 2022 [39]
NCT04428021		Three-arm blinded RCT on hospitalized COVID-19 patients; power 80%06/01/2020AD: 15%80%95%60 CCP + ST/60 ST/60 SP + ST60 CCP + ST/60 ST/60 SP + STNo30-day mortalityNoCCP + ST: 14/60 (23.3%)
ST: 12/60 (20.0%)
P = 0.69
PLACOVID, 2022 [40]
NCT04547660		Open-label RCT including hospitalized COVID-19 patients07/15/2020AD: 20%80%95%80 CCP + ST/80 ST80 CCP + ST/80 STNoProportion of patients with clinical improvement at day + 28NoCCP + ST: 18/80 (22.5%)
ST: 13/80 (16.3%)
P = 0.32
PlasmAr, 2021 [42]
NCT04383535		Double-blind, placebo-controlled RCT including severe COVID-19 patients05/28/2020OR: 1.880%95%222 CCP/111 PL228 CCP/105 PLNoPatient’s clinical status at 30 daysNoCCP: 25/228 (11.0%)
PL: 12/105 (11.4%)
P = NS
PROTECT, 2022 [44]
NCT04516811		Double-blind, phase III RCT including patients with moderate to severe COVID-1909/30/2020RD: 33%80%95%300 CCP/300 PL52 CCP/51 PLYes
(futility)		Clinical improvement at day 28NoCCP: 11/52 (21.5%)
PL: 13/51 (25.5%)
P = NS
Ray, 2022 [46]
CTRI/2020/05/025209		Open-label, phase II RCT including hospitalized COVID-19 patients 05/31/2020AD: 23%NRNR40 CCP/40 ST40 CCP/40 STNoAll-cause mortality by day 30NoCCP: 10/40 (25.0%)
ST: 14/40 (35.0%)
P = NS
RECOVERY, 2021 [47]
NCT04381936		Open-label RCT including hospitalized COVID-19 patients05/28/2020AD: 20%90%99%5500 CCP + ST/550 ST5795 CCP + ST/5763 STNo28-day mortalityNoCCP + ST: 1399/5795 (24.1%)
ST: 1408/5763 (24.4%)
P = 0.95
REMAP-CAP,
2021 [48]
NCT02735707		Open-label RCT including critically ill COVID-19 pts.03/09/2020OR: 1.2NRNRNR1075 CCP/904 PLNoMedian number of organ support-free daysNoCCP: 352/1074 (32.8%)
PL: 300/904 (33.2%)
P = NS
Rojas, 2022 [49]
NCT04332835		Single-blinded, parallel-controlled RCT in including hospitalized COVID-19 patients 08/08/2020RD: 30%90%95%46 CCP + ST/46 ST40 CCP + ST/43 STNoReduction in viral load at day 28NoCCP + ST: 6/46 (13.0%)
ST: 2/45 (4.4%)
P = 0.15
Saito, 2023 [50]Open-label RCT including hospitalized patients with mild COVID-1902/24/2021RD: 50%90%95%96 CCP/96 ST10 CCP/11 STYes
(vaccination coverage and mAB availability)		Time-weighted average change in the SARS-CoV-2 viral loadNoNo deaths recorded
TSUNAMI, 2021 [52]
NCT04716556		Open-label RCT including hospitalized COVID-19 patients07/15/2020RD:40%80%95%237 CCP + ST/237 ST231 CCP + ST/239 STNoComposite of worsening respiratory failure or death < 30 daysNoCCP + ST: 14/231 (6.1%)
ST: 19/239 (7.9%)
P = 0.43
Abbreviations: CCP, COVID-19 convalescent plasma; SP, standard plasma; RD, relative difference; CL, confidence level; ST, standard therapy; PL, placebo; NR, not reported; WHO, World Health Organization; HT-CCP, high-titer CCP; ST-CCP, standard-titer CCP; LT-CCP, low-titer CCP; NCT, National Clinical Trial identifier number; NS, not significant; mAbs, monoclonal antibodies; EUA, emergency use authorization; FDA, Food and Drug Administration; nAbs, neutralizing antibodies. 1 The size effect was reported as absolute difference (AD), relative difference (RD), or as an odds ratio (OR) in the primary outcome between cases and controls.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Franchini, M.; Mengoli, C.; Casadevall, A.; Focosi, D. Exploring Study Design Foibles in Randomized Controlled Trials on Convalescent Plasma in Hospitalized COVID-19 Patients. Life 2024, 14, 792. https://0-doi-org.brum.beds.ac.uk/10.3390/life14070792

AMA Style

Franchini M, Mengoli C, Casadevall A, Focosi D. Exploring Study Design Foibles in Randomized Controlled Trials on Convalescent Plasma in Hospitalized COVID-19 Patients. Life. 2024; 14(7):792. https://0-doi-org.brum.beds.ac.uk/10.3390/life14070792

Chicago/Turabian Style

Franchini, Massimo, Carlo Mengoli, Arturo Casadevall, and Daniele Focosi. 2024. "Exploring Study Design Foibles in Randomized Controlled Trials on Convalescent Plasma in Hospitalized COVID-19 Patients" Life 14, no. 7: 792. https://0-doi-org.brum.beds.ac.uk/10.3390/life14070792

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop